Pfizer Sutent Potential Adrenal Toxicity Concern Surfaced Early In FDA Review
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Review documents for Pfizer's Sutent show early, pre-NDA concern within FDA's oncology division relating to the multi-targeted tyrosine kinase inhibitor's potential to cause adrenal toxicity